BeStock  

Zimmer Biomet Holdings ZBH

US equityMarket cap rank #937Medical Devices
$101.10 −$0.37 (-0.36%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $100.82 -0.28%
Open$102.72
Prev close$101.47
Day range$100.82 – $103.87
Volume2.96M
Market cap$19.13B
P/E (TTM)25.5
Dividend yield0.95%

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$2.06B+3.1% YoY
Operating profit$341.50M+0.9% YoY
Net profit$192.90M-16.6% YoY
Diluted EPS$1.00-13.8% YoY
Free cash flow$459.20M+29.8% YoY
Operating cash flow$560.00M

Revenue, last 8 quarters

$2.0BDec '24$1.9BMar '25$2.1BJun '25$2.0BSep '25$2.2BDec '25$2.1BMar '26$2.2BJun '26$2.1BSep '26

Net profit, last 8 quarters

$240.1MDec '24$182.6MMar '25$153.4MJun '25$231.2MSep '25$137.9MDec '25$238.3MMar '26$199.6MJun '26$192.9MSep '26

Diluted EPS by quarter

1.20Dec '240.91Mar '250.77Jun '251.16Sep '250.71Dec '251.22Mar '261.03Jun '261.00Sep '26

Free cash flow by quarter

$421.4MDec '24$335.8MMar '25$298.1MJun '25$353.7MSep '25$432.6MDec '25$284.1MMar '26$331.4MJun '26$459.2MSep '26

Annual revenue

$6.1BFY20$6.8BFY21$6.9BFY22$7.4BFY23$7.7BFY24$8.2BFY25

Profitability & balance sheet

Gross margin69.7%
Operating margin16.3%
Net margin9.0%
Return on equity6.0%
Return on assets3.3%
Return on invested capital5.0%
Current ratio1.46
Liabilities / assets45.9%
Cash & investments$399.90M
Total debt$7.50B
Net cash (debt)-$7.10B
Free cash flow / sales17.6%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Knees$767.50M 37.2%
  • Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic (S.E.T)$578.30M 28.0%
  • Hips$536.50M 26.0%
  • Technology & Data, Bone Cement and Surgical$180.60M 8.8%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $2.06B $2.18B $2.09B $8.23B $2.24B
Total Operating Revenue $2.06B $2.18B $2.09B $8.23B $2.24B
Cost of Revenue $594.50M $635.50M $576.20M $2.49B $792.40M
Gross Profit $1.47B $1.54B $1.51B $5.74B $1.45B
Operating Expense $1.13B $1.17B $1.12B $4.38B $1.17B
Selling and Admin Expenses $855.00M $899.30M $849.90M $3.26B $872.30M
Research & Development $105.90M $104.80M $103.40M $458.50M $118.70M
Depreciation & Amortization & Depletion $166.00M $163.40M $162.10M $665.90M $177.70M
-Depreciation & Amortization $166.00M $163.40M $162.10M $665.90M $177.70M
Operating Profit $341.50M $374.00M $395.10M $1.36B $282.60M
Net Non-Operating Interest Income (Expense) -$74.90M -$72.90M -$68.80M -$292.80M -$71.90M
Non-Operating Interest Expense $74.90M $72.90M $68.80M $292.80M $71.90M
Other Income (Expense) -$36.50M -$46.00M -$24.90M -$232.60M -$112.80M
Special Income (Charges) -$34.00M -$47.90M -$21.90M -$258.10M -$128.20M
-Less:Restructuring and Mergern & Acquisition $34.00M $47.90M $21.90M $258.10M $128.20M
Other Non-Operating Income (Expenses) -$2.50M $1.90M -$3.00M $25.50M $15.40M
Pretax Profit $230.10M $255.10M $301.30M $830.80M $98.00M
Tax $37.20M $55.50M $63.00M $125.70M -$39.90M
Net Profit $192.90M $199.60M $238.30M $705.10M $137.90M
Profit from Continuing Operations $192.90M $199.60M $238.30M $705.10M $137.90M
Minority Interests $1.30M $1.30M $200,000.00 -$100,000.00 -$1.50M
Net Income to Parent Company $191.60M $198.30M $238.10M $705.10M $139.30M
Net Income to Common Stockholders $191.60M $198.30M $238.10M $705.10M $139.30M
Basic EPS $1.01 $1.03 $1.22 $3.56 $0.71
Diluted EPS $1.00 $1.03 $1.22 $3.55 $0.71
Dividend Per Share $0.24 $0.24 $0.24 $0.96 $0.24

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $23.54B $22.80B $22.72B $23.09B $23.09B
Total Current Assets $5.13B $5.10B $4.96B $5.12B $5.12B
Cash and Cash Equivalents & Short-Term Investments $399.90M $410.00M $424.20M $591.90M $591.90M
-Cash and Cash Equivalents $399.90M $410.00M $424.20M $591.90M $591.90M
Receivables $1.82B $1.77B $1.73B $1.70B $1.70B
-Accounts Receivable $1.82B $1.77B $1.73B $1.70B $1.70B
Inventory $2.37B $2.27B $2.25B $2.29B $2.29B
Other Current Assets $545.90M $646.90M $562.90M $537.20M $537.20M
Total Non-Current Assets $18.41B $17.70B $17.76B $17.97B $17.97B
Net PPE $2.31B $2.24B $2.21B $2.21B $2.21B
-Gross PPE $7.60B $7.42B $7.30B $7.26B $7.26B
-Accumulated Depreciation -$5.29B -$5.18B -$5.09B -$5.05B -$5.05B
Goodwill and Other Intangible Assets $14.97B $14.38B $14.48B $14.66B $14.66B
-Goodwill $10.34B $9.92B $9.93B $9.95B $9.95B
-Other Intangible Assets $4.64B $4.46B $4.55B $4.72B $4.72B
Other Non-Current Assets $1.13B $1.08B $1.07B $1.10B $1.10B
Total Liabilities $10.81B $10.17B $10.04B $10.39B $10.39B
Total Current Liabilities $3.50B $3.01B $2.86B $2.58B $2.58B
Payables $357.50M $352.40M $361.20M $303.00M $303.00M
-Accounts Payable $357.50M $352.40M $361.20M $303.00M $303.00M
Short-Term Debt and Capital Lease Obligation $1.29B $1.20B $1.18B $587.10M $587.10M
-Current Debt $1.29B $1.20B $1.18B $587.10M $587.10M
Other Current Liabilities $1.86B $1.13B $1.03B $382.00M $382.00M
Total Non-Current Liabilities $7.31B $7.15B $7.18B $7.80B $7.80B
Long Term Debt and Capital Lease Obligation $6.22B $6.28B $6.30B $6.93B $6.93B
-Long Term Debt $6.22B $6.28B $6.30B $6.93B $6.93B
Non-Current Deferred Liabilities $265.00M $235.60M $249.90M $244.10M $244.10M
Other Non-Current Liabilities $829.10M $638.70M $630.70M $626.10M $626.10M
Total Equity $12.73B $12.63B $12.68B $12.71B $12.71B
Stockholders' Equity $12.72B $12.62B $12.67B $12.70B $12.70B
Capital Stock $3.20M $3.20M $3.20M $3.20M $3.20M
-Common Stock $3.20M $3.20M $3.20M $3.20M $3.20M
Additional Paid-In Capital $10.26B $10.22B $10.20B $10.18B $10.18B
Retained Earnings $12.10B $11.96B $11.80B $11.61B $11.61B
Less: Treasury Stock -$9.47B -$9.39B -$9.14B -$8.89B -$8.89B
Gains/Losses Not Affecting Retained Earnings -$174.10M -$163.90M -$190.40M -$205.70M -$205.70M
Other Equity Interests $100,000.00 – – – –
Minority Interests $10.00M $8.70M $8.20M $8.10M $8.10M
Current Accrued Expenses – $334.30M $293.90M $1.31B $1.31B

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $560.00M $447.80M $359.40M $1.70B $517.40M
Net cash flow from continuing operations $560.00M $447.80M $359.40M $1.70B $517.40M
Net Income from Continuing Operations $193.00M $199.60M $238.30M $705.10M $137.90M
Depreciation & Depletion & Amortization $282.00M $270.80M $270.00M $1.09B $284.00M
Change in Working Capital $60.90M -$47.10M -$173.30M -$104.90M $158.60M
-Change in Receivables -$24.90M -$38.50M $14.50M -$127.30M -$111.70M
-Change in Inventory -$79.90M -$30.50M -$20.90M $98.20M $184.40M
-Change in Payables and Accrued Expense $121.60M $92.00M -$183.00M $101.80M $112.90M
-Change In Other Working Capital $44.10M -$70.10M $16.10M -$177.60M -$27.00M
Net cash flow from investing -$543.30M -$190.80M -$159.00M -$1.98B -$322.00M
Net Cash Flow from Continuing Investing Activities -$543.30M -$190.80M -$159.00M -$1.98B -$322.00M
Net PPE Purchase and Sale -$75.80M -$54.20M -$36.30M -$224.50M -$74.80M
Net Intangibles Purchase and Sale -$25.00M -$62.20M -$39.00M -$52.40M -$10.00M
Net Business Purchase and Sale -$359.40M – – -$1.39B -$166.90M
Net Investment Purchase and Sale -$83.10M -$74.30M -$77.50M -$300.90M -$69.40M
Net Other Investing Changes $0.00 -$100,000.00 -$6.20M -$4.70M -$900,000.00
Financing Cash Flow -$27.20M -$271.10M -$369.20M $326.00M -$897.00M
Net Cash Flow from Continuing Financing Activities -$27.20M -$271.10M -$369.20M $326.00M -$897.00M
Net Issuance Payments Of Debt $90.00M $30.00M $0.00 $1.03B -$600.00M
Net Common Stock Issuance -$78.50M -$250.70M -$250.10M -$487.00M -$250.00M
Cash Dividends Paid -$45.80M -$46.50M -$46.90M -$190.30M -$47.50M
Proceeds from Stock Option Exercised $13.40M $100,000.00 $12.30M $39.70M $1.70M
Net Other Financing Charges -$6.30M -$4.00M -$84.50M -$65.50M -$1.20M
Ending Cash Balance $399.90M $410.00M $424.20M $591.90M $591.90M
Net Change in Cash -$10.50M -$14.20M -$168.80M $47.40M -$701.60M
Beginning Cash Balance $410.00M $424.20M $591.90M $525.50M $1.29B
Effect of Exchange Rate Changes $400,000.00 $0.00 $1.10M $19.00M $800,000.00
Free Cash Flow $459.20M $331.40M $284.10M $1.42B $432.60M
Other Non-Cash Items – -$100,000.00 $200,000.00 $100,000.00 $0.00
Deferred Tax – – – -$87.20M –

Discussion

No comments yet — be the first to weigh in on ZBH.

Sign in to join the discussion.

Scroll to Top